tetano
Editor, Senior Moderator
Emerg Infect Dis. 2015;21(1):136-41. doi: 10.3201/eid2101.141006.
[h=1]Oseltamivir-Resistant Influenza A(H1N1)pdm09 Viruses, United States, 2013-14.[/h] Okomo-Adhiambo M, Fry AM, Su S, Nguyen HT, Elal AA, Negron E, Hand J, Garten RJ, Barnes J, Xiyan X, Villanueva JM, Gubareva LV; 2013?14 US Influenza Antiviral Working Group.
[h=3]Abstract[/h] We report characteristics of oseltamivir-resistant influenza A(H1N1)pdm09 viruses and patients infected with these viruses in the United States. During 2013-14, fifty-nine (1.2%) of 4,968 analyzed US influenza A(H1N1)pdm09 viruses had the H275Y oseltamivir resistance-conferring neuraminidase substitution. Our results emphasize the need for local surveillance for neuraminidase inhibitor susceptibility among circulating influenza viruses.
PMID: 25532050 [PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/25532050
[h=1]Oseltamivir-Resistant Influenza A(H1N1)pdm09 Viruses, United States, 2013-14.[/h] Okomo-Adhiambo M, Fry AM, Su S, Nguyen HT, Elal AA, Negron E, Hand J, Garten RJ, Barnes J, Xiyan X, Villanueva JM, Gubareva LV; 2013?14 US Influenza Antiviral Working Group.
[h=3]Abstract[/h] We report characteristics of oseltamivir-resistant influenza A(H1N1)pdm09 viruses and patients infected with these viruses in the United States. During 2013-14, fifty-nine (1.2%) of 4,968 analyzed US influenza A(H1N1)pdm09 viruses had the H275Y oseltamivir resistance-conferring neuraminidase substitution. Our results emphasize the need for local surveillance for neuraminidase inhibitor susceptibility among circulating influenza viruses.
PMID: 25532050 [PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/25532050